Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756)

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.22, Iss.6, 2012-06, pp. : 709-713

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-Lipoxygenase inhibitors: a patent evaluation (WO2011161615)

By Buscató Estel.la Proschak Ewgenij

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 7, 2012-07 ,pp. : 843-846

Informa Healthcare

Access to resources Recommend Favorite

1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284)

By Gilbert Eric J

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 1069-1073

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of influenza viruses replication: a patent evaluation (WO2013019828)

By Xie Yuanchao Song Weiguo Xiao Weidong Gu Changjuan Xu Wenfang

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 11, 2013-11 ,pp. : 1517-1524

Informa Healthcare

Access to resources Recommend Favorite

Protein kinase CK2 inhibitors: a patent review

By Cozza Giorgio Pinna Lorenzo A Moro Stefano

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 9, 2012-09 ,pp. : 1081-1097

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 3, 2012-03 ,pp. : 335-339

Informa Healthcare

Access to resources Recommend Favorite